LeukoDx Inc. Closes $7M Financing Round; Appoints Seymour Liebman & Mark Chess
TOWSON, MD and JERUSALEM, ISRAEL -- (Marketwired) -- 06/16/14 --
LeukoDx Inc., the creator of the Accellix automated flow cytometry
platform, today announced that it has secured $7 million in new
financing from Axcel Partners, a US-based private equity group, and
"We are grateful for this strong vote-of-confidence from both
existing and new investors," commented Mr. Julien Meissonnier,
LeukoDx's President and CEO. "Having secured this major cash
infusion, we will now accelerate our plans to bring the Accellix
platform and rapid sepsis test to market."
In parallel, the Company has appointed Mr. Mark Chess, a Managing
Director for Infinity Equity, and Mr. Seymour Liebman, a senior
executive officer of Canon Inc., to serve as members of the LeukoDx
Board of Directors.
"I am excited to help bring LeukoDx's exceptional technology -- a
solution for getting doctors life-and-death test results in minutes
rather than days -- to a health industry that remains stuck on so
many diagnostic fronts," commented Mr. Liebman. "I am confident that
LeukoDx's solutions will help raise the standards bar for healthcare
throughout the world."
"I am pleased to join the LeukoDx Board of Directors, a start-up
whose visionary founders and seasoned management have already made
impressive progress," stated Mr. Chess. "I look forward to helping
the team go the distance, bringing its needed technologies to large
and rapidly-growing markets."
Walter Drimer, Chairman of LeukoDx, added, "We are honored that both
Mark Chess and Seymour Liebman have agreed to join our Board. Their
outstanding international achievements and experience will be
extremely valuable to us as we proceed with the launch of the
Accellix platform and our first application, the Accellix Rapid
About LeukoDx Inc.
LeukoDx's mission is to deliver cost-effective,
highly sensitive and actionable diagnostic information at the point
of care via a novel automated IVD flow cytometry platform. Founded in
2009, LeukoDx's technology is based on technology initially developed
for NASA at CalTech. To date, the Company has developed a compact
reader for single use test-specific cartridges, and an application
for the rapid identification of sepsis, a condition associated with
high morbidity and mortality with no existing rapid diagnostic test.
About Mr. Mark Chess
Mr. Mark Chess, a Managing Director for
Infinity Equity, was actively involved in establishing the FBR
Infinity II Fund in 2001 and the world's first foreign currency fund
in China in 2005 (Infinity-CSVC). In 2007-2008, Mr. Chess helped
create the strategy and lead the development of the Infinity I-China
Fund, taking part in the activities that have made Infinity Equity
one of China's most prolific foreign investors. Currently, Mr. Chess
manages Infinity's strategic relationships with institutions in the
U.S., including the Infinity-NSF portfolio.
About Mr. Seymour Liebman
Mr. Seymour Liebman serves as Executive
Vice President, Chief Administrative Officer and General Counsel of
Canon U.S.A., Inc., as Vice Chairman of Canon Business Solutions,
Inc., and as a Senior Executive Officer of Canon Inc. in Japan. For
the past 40 years, Mr. Seymour has held a variety of management
positions at Canon U.S.A, Inc., and in 2009, became the first
non-Japanese individual to be elected to the position of Executive
Officer of Canon Inc. in Japan. Mr. Liebman is a Director and/or
officer of several Canon subsidiaries and affiliates in the U.S. He
is also a Board member of Zygo Corporation, a company in the process
of being acquired by Ametek, Inc. Mr. Liebman is an attorney admitted
to the Bar in New York, New Jersey and the District of Columbia and a
C.P.A. He holds a B.A. in Mathematics from Hofstra University, an
M.S. in Mathematics from Rutgers University, an M.S. in Accounting
from Long Island University and a J.D. from Touro Law School.
President and CEO
Press spacebar to pause and continue. Press esc to stop.